492 related articles for article (PubMed ID: 27167707)
21. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing.
Ratajska M; Krygier M; Stukan M; Kuźniacka A; Koczkowska M; Dudziak M; Śniadecki M; Dębniak J; Wydra D; Brozek I; Biernat W; Borg A; Limon J; Wasąg B
J Appl Genet; 2015 May; 56(2):193-8. PubMed ID: 25366421
[TBL] [Abstract][Full Text] [Related]
22. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
[TBL] [Abstract][Full Text] [Related]
23. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
25. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
[TBL] [Abstract][Full Text] [Related]
26. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
[TBL] [Abstract][Full Text] [Related]
27. High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families.
Riahi A; Kharrat M; Lariani I; Chaabouni-Bouhamed H
Fam Cancer; 2014 Dec; 13(4):603-9. PubMed ID: 25069718
[TBL] [Abstract][Full Text] [Related]
28. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
[TBL] [Abstract][Full Text] [Related]
29. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
[TBL] [Abstract][Full Text] [Related]
30. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
[TBL] [Abstract][Full Text] [Related]
31. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
32. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
34. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
35. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
37. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
[TBL] [Abstract][Full Text] [Related]
39. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
[TBL] [Abstract][Full Text] [Related]
40. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
Peixoto A; Salgueiro N; Santos C; Varzim G; Rocha P; Soares MJ; Pereira D; Rodrigues H; Bento MJ; Fráguas A; Moura G; Regateiro F; Castedo S; Teixeira MR
Fam Cancer; 2006; 5(4):379-87. PubMed ID: 16826315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]